Novavax: The Bear Case Is Broken, But The Bull Case Needs More Proof
Summary
- Novavax has transitioned into a royalty-driven model, with Q4 profitability and 73% of revenue from licensing and royalties.
- NVAX's FY26 revenue guidance of $230M–$270M reflects cleaner, high-margin cash flow, excluding potential $200M in milestones from Sanofi.
- With $857M in cash and receivables, NVAX is funded into 2028, but remains highly dependent on partner outcomes, especially Sanofi’s COVID/influenza program.
- I maintain a 'Hold' rating on NVAX, viewing it as appropriately valued and suitable only for speculative barbell portfolio positions given persistent high risks.
Recommended For You
About NVAX Stock
| Symbol | Last Price | % Chg |
|---|---|---|
| 10.01 | -5.92% | |
| Post | 10.07 | 0.60% |
Chart
Combination chart with 2 data series.
The chart has 1 X axis displaying Time. Data ranges from 2026-02-18 09:30:00 to 2026-03-18 16:00:00.
The chart has 1 Y axis displaying values. Data ranges from 8.565 to 11.88.
End of interactive chart.
More on NVAX
Related Stocks
| Symbol | Last Price | % Chg |
|---|---|---|
| 10.01 | -5.92% | |
| Post: | 10.07 | 0.60% |
Chart
Chart with 160 data points.
The chart has 1 X axis displaying Time. Data ranges from 2026-03-13 09:30:00 to 2026-03-18 16:00:00.
The chart has 1 Y axis displaying values. Data ranges from 9.995 to 10.885.
End of interactive chart.
Trending Analysis
Trending News
- 1
- 2
- 3
- 4
- 5
